Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drugging the Undruggable Ras — Immunotherapy to the Rescue?

7 Dec 2016

Abstract excerpt

Metastatic gastrointestinal cancers that express products of mutant KRAS genes have one of the most dismal outcomes of all solid tumors and present an unsolved problem in cancer medicine. An activating point mutation in one of genes encoding Ras was the first somatic point mutation identified in a human cancer, and its discovery established the role of somatic mutations as the common driver of oncogenesis.1,2 The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Colorectal Cancer Treatments and Studies
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27959676
DOI: 10.1056/nejme1612215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drugging the Undruggable Ras — Immunotherapy to the Rescue?PMID 27959676Read ↗

Mutated RAS: Targeting the “Untargetable” with T CellsSemantic proximity Read ↗

With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors.Semantic proximity Read ↗

Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.Semantic proximity Read ↗

RAS-targeted therapies: is the undruggable drugged?Semantic proximity Read ↗

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.Semantic proximity Read ↗

Drugging RAS: Know the enemy.Semantic proximity Read ↗

Targeting Mutant KRAS for Immunogenic Cell Death Induction.Semantic proximity Read ↗

GI-4000 in KRAS mutant cancers.Semantic proximity Read ↗

RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironmentSemantic proximity Read ↗

Rasal1 impairment unleashes anticancer immunity - a focus on T cellsSemantic proximity Read ↗

Kras and Tumor Immunity: Friend or Foe?Semantic proximity Read ↗

Adoptive T-Cell Therapy in Solid Tumor with KRASG12V/G12D MutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.